Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


08.01.2018

3 Ann Thorac Surg
1 Anticancer Res
1 Arch Pathol Lab Med
2 BMC Cancer
1 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
3 Cancer Res
1 Carcinogenesis
1 Clin Cancer Res
1 Clin Nucl Med
1 Eur J Cancer
2 Eur J Cardiothorac Surg
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
4 J Thorac Oncol
1 Lancet Oncol
16 Lung Cancer
1 Oncologist
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. BAISI A, Raveglia F, Rizzi A, Cioffi U, et al
    Using Biomarkers Serum Prognostic Factors For Non-Small Cell Lung Cancer: A Surgical Perspective.
    Ann Thorac Surg. 2018 Jan 3. pii: S0003-4975(17)31699.
    PubMed     Text format    

  2. GWOZDZ P, Pasieka-Lis M, Kolodziej K, Pankowski J, et al
    Prognosis of Patients with Stages I and II Non-Small Cell Lung Cancer With Nodal Micrometastases.
    Ann Thorac Surg. 2018 Jan 3. pii: S0003-4975(17)31704.
    PubMed     Text format     Abstract available

  3. SEDER CW, Liptay MJ, Borgia JA
    Using Biomarkers Serum Prognostic Factors for Non-small Cell Lung Cancer: A Surgical Perspective (Reply).
    Ann Thorac Surg. 2017 Dec 26. pii: S0003-4975(17)31629.
    PubMed     Text format    


    Anticancer Res

  4. HIGUCHI T, Yamamoto N, Hayashi K, Takeuchi A, et al
    The Efficacy of Wide Resection for Musculoskeletal Metastatic Lesions of Renal Cell Carcinoma.
    Anticancer Res. 2018;38:577-582.
    PubMed     Text format     Abstract available


    Arch Pathol Lab Med

  5. WALTS AE, Marchevsky AM
    Current Evidence Does Not Warrant Frozen Section Evaluation for the Presence of Tumor Spread Through Alveolar Spaces.
    Arch Pathol Lab Med. 2018;142:59-63.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. ZHOU J, Zheng J, Zhang X, Zhao J, et al
    Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    BMC Cancer. 2018;18:10.
    PubMed     Text format     Abstract available

  7. KANEDA T, Yoshioka H, Tamiya M, Tamiya A, et al
    Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    BMC Cancer. 2018;18:6.
    PubMed     Text format     Abstract available


    Cancer

  8. MANSOUR MSI, Seidal T, Mager U, Baigi A, et al
    Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Cancer. 2017;125:908-917.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  9. FEDORCHUK O, Susak Y, Rudyk M, Senchylo N, et al
    Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.
    Cancer Chemother Pharmacol. 2017 Dec 30. pii: 10.1007/s00280-017-3503.
    PubMed     Text format     Abstract available


    Cancer Lett

  10. WANG L, Syn NL, Subhash VV, Any Y, et al
    Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
    Cancer Lett. 2018 Jan 3. pii: S0304-3835(18)30003.
    PubMed     Text format     Abstract available


    Cancer Res

  11. KIDDER BL, He R, Wangsa D, Padilla-Nash HM, et al
    SMYD5 controls heterochromatin and chromosome integrity during embryonic stem cell differentiation.
    Cancer Res. 2017 Sep 26. pii: canres.0828.2017.
    PubMed     Text format     Abstract available

  12. ADELAIYE-OGALA R, Budka J, Damayanti NP, Arrington J, et al
    EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
    Cancer Res. 2017;77:6651-6666.
    PubMed     Text format     Abstract available

  13. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Text format     Abstract available


    Carcinogenesis

  14. YANG L, Wu D, Chen J, Chen J, et al
    A functional CNVR_3425.1 damping lincRNA FENDRR increases lifetime risk of lung cancer and COPD in Chinese.
    Carcinogenesis. 2017 Dec 23. pii: 4774028. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  15. LIU S, Li S, Hai J, Wang X, et al
    Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
    Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-1875.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  16. XIE P, Huang J
    Solitary Thumb Acrometastasis Identified on Bone Scintigraphy.
    Clin Nucl Med. 2017 Feb 24. doi: 10.1097/RLU.0000000000001621.
    PubMed     Text format     Abstract available


    Eur J Cancer

  17. SNEE M
    Quality of life comparing carboplatin with cisplatin in the treatment of non-small cell lung cancer.
    Eur J Cancer. 2018 Jan 2. pii: S0959-8049(17)31427.
    PubMed     Text format    


    Eur J Cardiothorac Surg

  18. TAMBURINI N, Maniscalco P, Mazzara S, Maietti E, et al
    Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study.
    Eur J Cardiothorac Surg. 2017 Dec 25. pii: 4774618. doi: 10.1093.
    PubMed     Text format     Abstract available

  19. XIE D, Allen MS, Marks R, Jiang G, et al
    Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.
    Eur J Cardiothorac Surg. 2017 Dec 27. pii: 4780277. doi: 10.1093.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  20. ITO K, Shimizuguchi T, Nihei K, Furuya T, et al
    Patterns of Intraosseous Recurrence After Stereotactic Body Radiation Therapy for Coxal Bone Metastasis.
    Int J Radiat Oncol Biol Phys. 2018;100:159-161.
    PubMed     Text format     Abstract available

  21. POULSEN PR, Eley J, Langner U, Simone CB 2nd, et al
    Efficient Interplay Effect Mitigation for Proton Pencil Beam Scanning by Spot-Adapted Layered Repainting Evenly Spread out Over the Full Breathing Cycle.
    Int J Radiat Oncol Biol Phys. 2018;100:226-234.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. LIAO Z, Lee JJ, Komaki R, Gomez DR, et al
    Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jan 2:JCO2017740720. doi: 10.1200/JCO.2017.74.0720.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  23. LANUTI M
    Risk stratification for distant recurrence of resected early stage non-small cell lung cancer is under construction.
    J Thorac Cardiovasc Surg. 2017 Nov 1. pii: S0022-5223(17)32392.
    PubMed     Text format    


    J Thorac Oncol

  24. SAXON JA, Sholl LM, Janne PA
    EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    J Thorac Oncol. 2017;12:884-889.
    PubMed     Text format     Abstract available

  25. ZHAO ZR, Situ DR, Lau RWH, Mok TSK, et al
    Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
    J Thorac Oncol. 2017;12:890-896.
    PubMed     Text format     Abstract available

  26. THORNE-NUZZO T, Williams C, Catallini A, Clements J, et al
    A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    J Thorac Oncol. 2017;12:804-813.
    PubMed     Text format     Abstract available

  27. RANGACHARI D, VanderLaan PA, Shea M, Le X, et al
    Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:878-883.
    PubMed     Text format     Abstract available


    Lancet Oncol

  28. CHENG H, Perez-Soler R
    Leptomeningeal metastases in non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e43-e55.
    PubMed     Text format     Abstract available


    Lung Cancer

  29. LIU E, Guha A, Jia K, Ayers AM, et al
    Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
    Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
    PubMed     Text format    

  30. TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
    Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Lung Cancer. 2018;115:49-55.
    PubMed     Text format     Abstract available

  31. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
    Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
    PubMed     Text format    

  32. NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
    A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer. 2018;115:103-108.
    PubMed     Text format     Abstract available

  33. KHAN SA, Pruitt SL, Xuan L, Makris U, et al
    How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
    Lung Cancer. 2018;115:97-102.
    PubMed     Text format     Abstract available

  34. LEE J, Kim HK, Park BJ, Cho JH, et al
    Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lung Cancer. 2018;115:89-96.
    PubMed     Text format     Abstract available

  35. TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
    Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Lung Cancer. 2018;115:84-88.
    PubMed     Text format     Abstract available

  36. YANG CJ, Gu L, Shah SA, Yerokun BA, et al
    Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
    Lung Cancer. 2018;115:75-83.
    PubMed     Text format     Abstract available

  37. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2018;115:71-74.
    PubMed     Text format     Abstract available

  38. HUANG HC, Su WJ, Chiang CL, Feng JY, et al
    The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2018;115:64-70.
    PubMed     Text format     Abstract available

  39. THAWANI R, McLane M, Beig N, Ghose S, et al
    Radiomics and radiogenomics in lung cancer: A review for the clinician.
    Lung Cancer. 2018;115:34-41.
    PubMed     Text format     Abstract available

  40. ISAKA M, Kojima H, Takahashi S, Omae K, et al
    Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Lung Cancer. 2018;115:28-33.
    PubMed     Text format     Abstract available

  41. EVISON M, Edwards T, Balata H, Tempowski A, et al
    Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
    Lung Cancer. 2018;115:127-130.
    PubMed     Text format     Abstract available

  42. SOO RA, Lim SM, Syn NL, Teng R, et al
    Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Lung Cancer. 2018;115:12-20.
    PubMed     Text format     Abstract available

  43. TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
    Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Lung Cancer. 2018;115:116-120.
    PubMed     Text format     Abstract available

  44. LIU X, Jiang T, Li W, Li X, et al
    Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
    Lung Cancer. 2018;115:109-115.
    PubMed     Text format     Abstract available


    Oncologist

  45. BARSANTI-INNES B, Hey SP, Kimmelman J
    The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.
    Oncologist. 2017;22:89-96.
    PubMed     Text format     Abstract available


    PLoS One

  46. GALLARDO-ESTRELLA L, Pompe E, de Jong PA, Jacobs C, et al
    Normalized emphysema scores on low dose CT: Validation as an imaging biomarker for mortality.
    PLoS One. 2017;12:e0188902.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: